Literature DB >> 21453249

An updated patent review on ocular drug delivery systems with potential for commercial viability.

Rishabh Srivastava1, Kamla Pathak.   

Abstract

The eye due to its special attributes is an effortlessly accessible location for topical drug administration. Topical administration not only provides local targeting of drugs but also offers a better control over the systemic delivery. Bioavailability of drugs from ocular dosage forms is dependent to the precorneal loss factors (physiological and anatomical constraints of eye) thus, very small fraction of the drug is absorbed through ocular route. The effective dose of medication administered ophthalmically may be altered by changing the formulation. Various research reports have been documented for ocular drug delivery, both on academic level as well as commercial level resulting in augmented increase in the numbers of patents in this field. The primary objective of the present review is to provide an overview of the ocular drug delivery systems with special emphasis on the intellectual aspects of these systems. This paper also attempts to extend the information on ocular drug delivery systems already existing in the literature by focusing on the update on the patents granted as well as applications published for these systems during the last decade.

Mesh:

Substances:

Year:  2011        PMID: 21453249     DOI: 10.2174/187221111795471436

Source DB:  PubMed          Journal:  Recent Pat Drug Deliv Formul        ISSN: 1872-2113


  1 in total

1.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.